Literature DB >> 14709249

A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions.

Matthew E Harris1, Shlomo Maayan, Bohye Kim, Michael Zeira, Guido Ferrari, Deborah L Birx, Francine E McCutchan.   

Abstract

The impact of HIV-1 genetic diversity on candidate vaccines is uncertain. One approach to minimize genetic diversity in the evaluation of HIV-1 vaccines is to match the vaccine sequence to the predominant subtype in a vaccine cohort. Over two million Ethiopians are infected with HIV-1, and the predominant subtype is thought to be subtype C. Understanding the phylogenetic relationships between sequences from Ethiopia and within subtype C can help decide what sequence(s) should comprise a candidate vaccine. To that end, nearly full genome sequencing was used to characterize HIV-1 from volunteers who emigrated from Ethiopia. DNA extracted from peripheral blood mononuclear cells (PMBC) was amplified using primers in the long terminal repeats to generate nearly full-length genomes. Amplicons were directly sequenced with dye terminators and automated sequencers. Sequences were phylogenetically analyzed by neighbor joining. The six new Ethiopian sequences were all subtype C, consistent with previous partial and full genome analysis. Together with two other Ethiopian sequences, the new sequences formed a geographic cluster when the complete genome was analyzed. However, subgenomic trees showed only a weak geographic cluster, or none, with respect to Ethiopian strains. Although immunological responses must be considered, from a phylogenetic perspective, there is no compelling support for use of Ethiopian subtype C sequences, compared to other subtype C, as vaccine prototype strains.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14709249     DOI: 10.1089/088922203771881220

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  Importance of Viral Sequence Length and Number of Variable and Informative Sites in Analysis of HIV Clustering.

Authors:  Vlad Novitsky; Sikhulile Moyo; Quanhong Lei; Victor DeGruttola; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2015-02-06       Impact factor: 2.205

2.  Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.

Authors:  Meiqing Lu; Peter J Felock; Vandna Munshi; Renee C Hrin; Ying-Jie Wang; Youwei Yan; Sanjeev Munshi; Georgia B McGaughey; Robert Gomez; Neville J Anthony; Theresa M Williams; Jay A Grobler; Daria J Hazuda; Philip M McKenna; Michael D Miller; Ming-Tain Lai
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.

Authors:  Bruce K Brown; Janice M Darden; Sodsai Tovanabutra; Tamara Oblander; Julie Frost; Eric Sanders-Buell; Mark S de Souza; Deborah L Birx; Francine E McCutchan; Victoria R Polonis
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Extensive intrasubtype recombination in South African human immunodeficiency virus type 1 subtype C infections.

Authors:  Christine M Rousseau; Gerald H Learn; Tanmoy Bhattacharya; David C Nickle; David Heckerman; Senica Chetty; Christian Brander; Philip J R Goulder; Bruce D Walker; Photini Kiepiela; Bette T Korber; James I Mullins
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

5.  Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.

Authors:  Ming-Tain Lai; Vandna Munshi; Sinoeun Touch; Robert M Tynebor; Thomas J Tucker; Philip M McKenna; Theresa M Williams; Daniel J DiStefano; Daria J Hazuda; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.